NSABP P-2: STAR

NSABP P-2：明星

• 批准号: 7607571
• 负责人: Scott Henry Kurtzman
• 金额: $ 1.6万
• 依托单位: UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607571
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Development; Endometrial Carcinoma; Evaluation; Funding; Goals; Grant; In Situ; Incidence; Institution; Invasive; National Surgical Adjuvant Breast and Bowel Project; Osteoporosis prevention; Outcome; P-2; Patients; Pharmaceutical Preparations; Postmenopause; Raloxifene; Rate; Research; Research Personnel; Resources; Source; Tamoxifen; United States National Institutes of Health; Woman; disorder risk; malignant breast neoplasm; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In the P-1 study, tamoxifen was shown to prevent the development of invasive and in situ breast cancer. Raloxifene has shown to be an effective drug for the prevention of osteoporosis. It was observed in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial that there were fewer breast cancers in the group of patients that had taken raloxifene compared to the controls. This study will determine if raloxifene is either more or less effective than tamoxifen in reducing the incidence of invasive breast cancer in postmenopausal women who are at increased risk for the disease. A secondary goal is to determine whether raloxifene reduces the endometrial cancer rate compared to tamoxifen.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 在P-1研究中，他莫昔芬被证明可以预防浸润性和原位乳腺癌的发展。 雷洛昔芬已被证明是预防骨质疏松症的有效药物。 在雷洛昔芬多结局评价（MORE）试验中观察到，与对照组相比，服用雷洛昔芬的患者组乳腺癌发生率更低。 这项研究将确定雷洛昔芬是否比他莫昔芬更有效或更有效地降低绝经后妇女浸润性乳腺癌的发病率，这些妇女患浸润性乳腺癌的风险增加。 第二个目标是确定雷洛昔芬是否与他莫昔芬相比降低子宫内膜癌发生率。